NEW YORK (TheStreet) -- Can shares of Puma Biotechnology (PBYI) rebound? That's one of the big questions on the minds of investors at the year's biggest cancer research event, the American Society of Clinical Oncology meeting, which began Friday in Chicago.

Puma's shares sank earlier this month on an initial data release for its breast cancer drug, neratinib, ahead of the meeting. The results fell short of analysts' and investors' expectations, and weighed not only on the stock price but also on the company's potential prospects for a sale. Puma is likely hoping to change investors' minds about the drug's prospects.

Others at the conference were intensely focused on immunotherapies -- drugs that harness the immune system to fight cancer -- from Bristol-Myers Squibb (BMY), Merck (MRK), AstraZeneca (AZN), Roche (RHHBY) and others, as well as on a number of targeted therapies for lung, breast and other cancers.

RBC Capital Markets analyst Simos Simeonidis said he sees the potential for a rebound in Puma shares coming out of ASCO. "We reiterate our view that neratinib's phase 3 ExteNET data were positive and misread by many in the market following release of the ASCO abstracts two weeks ago," Simeonidis wrote in a May 27 research note, referring to the name of Puma's clinical trial. "We continue to expect that the full data presentation and Puma's investor meeting will help clarify the data."

If you liked this article you might like

Blue Apron, Philip Morris, Honeywell, Becton Dickinson: 'Mad Money' Lightning Round

Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)

5 New Breast Cancer Treatments That Are Helping to Save Lives

Puma Up as Breast Cancer Program Gets Green Light; Nektar's Oxycodon Comp. Gets Praise

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)